Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
The Role of Diet in Inflammatory Bowel Disease Onset, Disease Management, and Surgical Optimization
Publication Year: 2025 Source: Am J Gastroenterol PMID: 39298569
No Abstract
Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39298676
BACKGROUND: Optimal treatment strategies for seton use in patients with Crohn's perianal fistulas (CPF) remain elusive. This systematic literature review aimed to summarize clinical, patient-reported, and healthcare resource utilization (HCRU) outcomes associated with seton use for symptomatic relief and treatment of complex CPF. METHODS: Electronic databases (MEDLINE, Embase, EBM Reviews, …
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study
Publication Year: 2025 Source: Dig Liver Dis PMID: 39299813 DOI: 10.1016/j.dld.2024.08.040
BACKGROUND AND AIM: Suboptimal disease control (SDC) and its contributing factors in IBD according to STRIDE-II criteria is unclear. IBD-PODCAST was a non-interventional, international, multicenter real-world study to assess this. METHODS: Data from the Italian IBD cohort (N=220) are presented here. Participants aged >/=19 with confirmed IBD diagnosis of >/=1 …
A Systematic Review and Metaanalysis to Examine the Utility of Histological Parameters Such as Mucosal Basal Plasmacytosis and Eosinophilia for Distinguishing Inflammatory Bowel Disease and Non-IBD-Type Colitis
Publication Year: 2025 Source: Int J Surg Pathol PMID: 39300818 DOI: 10.1177/10668969241271352
Background and aim: Basic differentiation between an inflammatory bowel disease (IBD)-type colitis and a non-IBD type of colitis is the essential histological pre-requisite before further subclassifications are made. The combination of mucosal prominent eosinophilic cell infiltrate along with basal plasmacytosis is supposed to be a useful histological feature that can …
Limiting Opioid Use for Patients Who Are Hospitalized for Inflammatory Bowel Disease Exacerbations
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39301671
No Abstract
Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39301678
No Abstract
Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease
Publication Year: 2025 Source: J Crohns Colitis PMID: 39302135 DOI: 10.1093/ecco-jcc/jjae151
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) trials often stratify patients by prior biologic exposure, including prior biologic failure or intolerance. This study aimed to assess clinical outcomes in IBD patients with prior biologic failure vs intolerance treated with ustekinumab or vedolizumab. METHODS: A post-hoc analysis of ulcerative colitis (UC) …
Cimifugin improves intestinal barrier dysfunction by upregulating SIRT1 to regulate the NRF2/HO-1 signaling pathway
Publication Year: 2025 Source: Naunyn Schmiedebergs Arch Pharmacol PMID: 39302422
No Abstract
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39303214
BACKGROUND: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants. …
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 39303799 DOI: 10.1016/j.cgh.2024.08.028
BACKGROUND & AIMS: Heterogeneity of treatment effects in inflammatory bowel disease (IBD) means that many individuals or patient subgroups depart from the average for whom the outcomes from traditional randomized trials may not be applicable. The N-of-1 trial is a design in which a single patient is followed over time …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide